Results per Page:
Humanized mice and in vivo therapeutic production? This is not science fiction
From the Richard James Lab, Seattle Children’s Research Institute and the Cancer Consortium
New clinical trials to target HER2 positive solid cancers
From Dr. Sara Hurvitz, Clinical Research Division, and colleagues
Anti-(idio)typical: a new immunogen to vaccinate against RSV
From the McGuire Lab, Vaccine & Infectious Disease Division
Going straight to the source in defense against infant RSV
New anti-idiotype antibody a first step in possible strategy to build infant immunity during vulnerable window
The past, present, and future of antibody-based pandemic protection
From the Bloom Lab, Basic Sciences Division
How studies of coronavirus immunity can inform better vaccines, treatments
Scientists look for broad-acting antibodies that could protect against new variants of SARS-CoV-2 — and maybe a future SARS-3
Taking aim: Mesothelin as a novel target for pediatric AML therapy
From the Meshinchi Lab, Clinical Research Division, and Cancer Consortium colleagues
Keep your enemies closer: targeting membrane-proximal domains for improved immunotherapy
From the Walter Lab, Clinical Research Division
Antibodies a hot topic in COVID-19 research
Hutch scientists tap their antibody expertise for new tests, treatments, vaccines
Mixing antibodies in silico: is more better?
From the Bloom Lab, Basic Sciences Division
Gimme shelter: CRISPR hides healthy cells from leukemia drug
In mouse study, gene-edited cells stay safe as immunotherapy attacks cancer
Double trouble: epithelial and B cell neutralization of Epstein-Barr virus
McGuire Laboratory, Vaccine and Infectious Disease Division